Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases

详细信息    查看全文

• 作者：Luc J. Farmer ; Mark W. Ledeboer ; Thomas Hoock ; Michael J. Arnost ; Randy S. Bethiel ; Youssef L. Bennani ; James J. Black ; Christopher L. Brummel ; Ananthsrinivas Chakilam ; Warren A. Dorsch ; Bin Fan ; John E. Cochran ; Summer Halas ; Edmund M. Harrington ; James K. Hogan ; David Howe ; Hui Huang ; Dylan H. Jacobs ; Leena M. Laitinen ; Shengkai Liao ; Sudipta Mahajan ; Valerie Marone ; Gabriel Martinez-Botella ; Pamela McCarthy ; David Messersmith ; Mark Namchuk ; Luke Oh ; Marina S. Penney ; Albert C. Pierce ; Scott A. Raybuck ; Arthur Rugg ; Francesco G. Salituro ; Kumkum Saxena ; Dean Shannon ; Dina Shlyakter ; Lora Swenson ; Shi-Kai Tian ; Christopher Town ; Jian Wang ; Tiansheng Wang ; M. Woods Wannamaker ; Raymond J. Winquist ; Harmon J. Zuccola
• 刊名：Journal of Medicinal Chemistry
• 出版年：2015
• 出版时间：September 24, 2015
• 年：2015
• 卷：58
• 期：18
• 页码：7195-7216
• 全文大小：864K
• ISSN：1520-4804

文摘

While several therapeutic options exist, the need for more effective, safe, and convenient treatment for a variety of autoimmune diseases persists. Targeting the Janus tyrosine kinases (JAKs), which play essential roles in cell signaling responses and can contribute to aberrant immune function associated with disease, has emerged as a novel and attractive approach for the development of new autoimmune disease therapies. We screened our compound library against JAK3, a key signaling kinase in immune cells, and identified multiple scaffolds showing good inhibitory activity for this kinase. A particular scaffold of interest, the 1H-pyrrolo[2,3-b]pyridine series (7-azaindoles), was selected for further optimization in part on the basis of binding affinity (K_i) as well as on the basis of cellular potency. Optimization of this chemical series led to the identification of VX-509 (decernotinib), a novel, potent, and selective JAK3 inhibitor, which demonstrates good efficacy in vivo in the rat host versus graft model (HvG). On the basis of these findings, it appears that VX-509 offers potential for the treatment of a variety of autoimmune diseases.